Evolution of the Average Target: AstraZeneca PLC

Evolution of the Average Target - AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Evolution of the Target Price - AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

c9a2b3534bbb.CyyxRQ2-YdXHUNJFIZy4jCJRBQYD-ow2J6dWWNNXSSU.bl_-DXzLO72QaZYOQuvOvkonalRzm8gDb5UUHJEaeWgye8QTVdQugZJp6g~20daefe9a5b1303065454d3192c26278
10-28 AstraZeneca PLC : Deutsche Bank remains Neutral ZD
10-27 AstraZeneca PLC : Receives a Buy rating from Jefferies ZD
10-27 AstraZeneca PLC : JP Morgan reaffirms its Buy rating ZD
10-27 AstraZeneca PLC : RBC maintains a Buy rating ZD
10-26 AstraZeneca PLC : JP Morgan reaffirms its Buy rating ZD
10-21 AstraZeneca PLC : Gets a Buy rating from JP Morgan ZD
10-20 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
10-16 AstraZeneca PLC : Berenberg remains its Buy rating ZD
10-15 RBC Reaffirms AstraZeneca's Outperform Rating Ahead of Q3 Results MT
10-15 AstraZeneca PLC : UBS gives a Buy rating ZD
10-15 AstraZeneca PLC : Gets a Buy rating from RBC ZD
10-14 AstraZeneca PLC : Deutsche Bank reiterates its Neutral rating ZD
10-07 Berenberg Trims AstraZeneca PT, Affirms Outperform Rating MT
10-07 Deutsche Bank ups Glencore, BHP price targets AN
10-07 AstraZeneca PLC : Buy rating from Berenberg ZD
10-07 AstraZeneca PLC : Jefferies gives a Buy rating ZD
10-07 AstraZeneca PLC : Bernstein reaffirms its Buy rating ZD
10-06 Genmab in Good Health, Schneider Lacks Energy Zonebourse
10-06 BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum MT
09-30 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating ZD
09-29 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
09-29 Stocks Defy the Pressure Zonebourse
09-29 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
09-29 AstraZeneca PLC : RBC reaffirms its Buy rating ZD
09-29 AstraZeneca PLC : JP Morgan maintains a Buy rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+3.53%
+3.09%
-0.98%
-2.95%
+13.36%
-1.36%
+23.73%
-12.06%
+0.62%
Average +3.00%
Weighted average by Cap. +3.00%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
169.90USD
Average target price
210.05USD
Spread / Average Target
+23.63%
High Price Target
262.96USD
Spread / Highest target
+54.77%
Low Price Target
154.83USD
Spread / Lowest Target
-8.87%

Analyst Consensus Detail

Analyst consensus - AstraZeneca PLC

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AstraZeneca PLC
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC